UK markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
22.15-0.34 (-1.51%)
At close: 04:00PM EDT
22.10 -0.05 (-0.23%)
After hours: 04:23PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.09B
Enterprise value 1.96B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.81
Price/book (mrq)2.61
Enterprise value/revenue 5.70
Enterprise value/EBITDA -13.52

Trading information

Stock price history

Beta (5Y monthly) 1.26
52-week change 3-13.40%
S&P500 52-week change 318.47%
52-week high 334.78
52-week low 321.57
50-day moving average 325.27
200-day moving average 327.34

Share statistics

Avg vol (3-month) 3607.8k
Avg vol (10-day) 3848.56k
Shares outstanding 5137.42M
Implied shares outstanding 6137.42M
Float 8123.75M
% held by insiders 114.63%
% held by institutions 180.44%
Shares short (30 Aug 2023) 49.09M
Short ratio (30 Aug 2023) 415.06
Short % of float (30 Aug 2023) 47.86%
Short % of shares outstanding (30 Aug 2023) 46.62%
Shares short (prior month 30 Jul 2023) 48.69M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin -37.42%
Operating margin (ttm)-47.55%

Management effectiveness

Return on assets (ttm)-7.85%
Return on equity (ttm)-12.40%

Income statement

Revenue (ttm)343.11M
Revenue per share (ttm)2.59
Quarterly revenue growth (yoy)460.40%
Gross profit (ttm)-250.27M
EBITDA -144.6M
Net income avi to common (ttm)-128.38M
Diluted EPS (ttm)-1.09
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.19B
Total cash per share (mrq)8.67
Total debt (mrq)55.52M
Total debt/equity (mrq)4.68%
Current ratio (mrq)17.65
Book value per share (mrq)8.64

Cash flow statement

Operating cash flow (ttm)-301.68M
Levered free cash flow (ttm)-265.38M